Breaking Finance News

ValuEngine downgraded Marinus Pharmaceuticals Inc (NASDAQ:MRNS) to Strong Sell in a report released today.

Yesterday Marinus Pharmaceuticals Inc (NASDAQ:MRNS) traded 2.54% higher at $1.36. The company’s 50-day moving average is $1.70 and its 200-day moving average is $1.45. The last stock close price is down 66.60% from the 200-day moving average, compared to the S&P 500 which has increased 0.05% over the same time. 910,474 shares of the stock were exchanged, up from an average trading volume of 461,886

ValuEngine has downgraded Marinus Pharmaceuticals Inc (NASDAQ:MRNS) to Strong Sell in a report released on Friday July 07, 2017.

See Chart Below

Marinus Pharmaceuticals Inc (NASDAQ:MRNS)

Marinus Pharmaceuticals Inc has a 52 week low of $0.82 and a 52 week high of $2.73 The company’s market cap is currently $0.

In addition to ValuEngine reporting its target price, a total of 5 firms have reported on the stock. The consensus target price is $16.20 with 3 firms rating the stock a strong buy, 2 firms rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

About Marinus Pharmaceuticals Inc (NASDAQ:MRNS)

Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings. Ganaxolone acts on the GABAA receptor, a target in the brain known for both anti seizure and anti anxiety effects through positive allosteric modulation. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.